Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, July 15, 2026, 1:00-2:00 PM ET
Hear an expert discuss how to integrate Kappa and Lambda in situ hybridization testing into your standard hematopathology workflow to accurately assess B-cell and plasma cell clonality. You will also gain the skills to recognize testing pitfalls in challenging reactive versus neoplastic proliferations and apply ancillary tools to resolve complex cases.
Webinar presenter Xiaojun Wu, MD, PhD, Assistant professor, Director of Hematopathology Section at NCR of Johns Hopkins Medicine Department of Pathology, SOM at Johns Hopkins University
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
July 17, 2024—Diasorin announced that the FDA has granted de novo authorization for the Simplexa C. auris Direct kit to test patients suspected of Candida auris colonization and aid in preventing potential spread in health care settings.
July 16, 2024—T-Neuro Pharma announced the publication of a landmark research article in Proceedings of the National Academy of Sciences (Panwar A, et al. Proc Natl Acad Sci USA. 2024;121(29):e2401420121).
July 12, 2024—Thermo Fisher Scientific is partnering with the National Cancer Institute on the myeloMATCH (Molecular Analysis for Therapy Choice) precision medicine umbrella trial to help accelerate research into new treatments for acute myeloid leukemia and myelodysplastic syndrome.
July 2, 2024—Cepheid has received FDA de novo marketing authorization and CLIA waiver approval for its Xpert HCV, the first point-of-care hepatitis C RNA test.
July 1, 2024—TechLab, a part of SSI Diagnostica Group, announced that its C. Diff Quik Chek Complete test has received certification under European in vitro diagnostic medical device regulation.
June 28, 2024—Siemens Healthineers has added the NT‑proBNPII assay to its cardiac test menu on the Atellica Solution to help diagnose heart failure.
June 27, 2024—BioMérieux announced that its Biofire Spotfire Respiratory/Sore Throat (R/ST) Panel Mini has received FDA special 510(k) clearance and CLIA waiver.
June 26, 2024—Proscia has partnered with Nucleai, a spatial artificial intelligence biomarker company that maps protein expression and cellular interactions within tissue samples to predict therapeutic outcomes.
June 25, 2024—Horiba announced that it has expanded its compact hematology instrument range with the launch of three models now with erythrocyte sedimentation rate onboard.
June 24, 2024—Cone Health and Risant Health have signed a definitive agreement under which Cone Health will become part of Risant Health, pending regulatory approvals.
